BALTIMORE — Glenmark Pharmaceuticals has gotten the okay from the Food and Drug Administration for solifenacin succinate tablets, in 5 mg and 10 mg dosages strengths.

Solifenacin succinate tablets are the generic of Astellas Pharma’s Vesicare tablets, 5 mg and 10 mg.

The product had a market value of roughly $942.7 million for the 12 month period ending March 2019, according to IQVIA.